CJC-1295 No DAC and Ipamorelin: Research Memory Considerations

CJC-1295 no DAC and ipamorelin are studied side by side because they act on two different receptors that feed the same growth hormone axis — one is a growth hormone releasing hormone (GHRH) analog, the other a selective ghrelin-receptor agonist. Interest in memory-related endpoints comes from preclinical literature suggesting that GH/IGF-1 signaling and ghrelin-receptor activity both intersect with hippocampal function, but that body of work is early, largely animal-model, and does not support any claim about people. For a wholesale buyer, the practical considerations are twofold: understand the honest state of that science before you describe it to anyone, and understand that cognition-adjacent research designs are unusually unforgiving of impure or inconsistent material.

Both compounds are supplied strictly for laboratory research use. Nothing below is dosing guidance, an administration protocol, or a statement about outcomes in humans or animals.

Two receptors, one axis — why the pair gets studied together

CJC-1295 without DAC is a synthetic analog built on the GRF(1-29) fragment of growth hormone releasing hormone, with amino acid substitutions intended to resist enzymatic degradation. Because it lacks the Drug Affinity Complex modification that binds the DAC version to albumin, its activity window is short rather than sustained. That matters to researchers for a structural reason, not a marketing one: the GH axis signals in pulses, and a short-acting GHRH analog stays closer to that native rhythm than a long-acting one. Study designs that care about pulsatility — and most GH-axis work does — tend to specify the no-DAC form for exactly this reason. Real Peptides lists it as CJC-1295 No DAC 10mg in the research catalog.

Ipamorelin is a pentapeptide agonist at the growth hormone secretagogue receptor, GHS-R1a — the same receptor ghrelin binds. Early characterization work described it as comparatively selective among secretagogues, with limited activity at the pathways that made older compounds messy to interpret. Selectivity is the reason it appears in so many mechanistic designs: fewer confounding signals means fewer competing explanations for whatever the assay shows. It is catalogued as Ipamorelin 10mg.

The pairing exists because the two act on distinct receptors that converge on the same downstream output. Researchers investigating the axis frequently want to see whether stimulating both inputs produces a different signaling profile than either alone. Whether that convergence translates into anything meaningful for cognition endpoints is a separate question — and a much less settled one.

What the memory literature supports, and where it stops

The mechanistic rationale for looking at memory endpoints is real, and it is also narrower than most marketing copy implies.

Growth hormone and IGF-1 receptors are expressed in regions of the brain associated with learning and memory, including the hippocampus. Preclinical research suggests IGF-1 signaling participates in synaptic plasticity and neurogenesis in animal models. Separately, GHS-R1a is expressed in hippocampal tissue, and studies in rodent models indicate ghrelin-receptor signaling can influence measures of synaptic density and performance on spatial memory tasks. Those are the two threads that make the GH axis interesting to anyone studying cognition.

Here is where honest framing has to take over. Most of that literature examines ghrelin itself, or exogenous growth hormone, or IGF-1 directly — not these two specific analogs. Extending a finding about a native ligand to a synthetic secretagogue is an inference, not a result. Blood-brain barrier permeability for peptides of this size remains an open methodological question, which means a central effect and a peripherally mediated effect are difficult to separate without deliberate study design. Species differences are substantial. Age, sex, baseline axis function, and circadian timing all move the results. And a secretagogue-driven signaling profile is not equivalent to administered growth hormone, so findings do not transfer cleanly between the two approaches.

For a business buyer, the takeaway is simple and worth internalizing: the mechanism is a legitimate reason for researchers to be interested, and it is not evidence of a benefit in people. Anything you publish, say, or put on a label should stay on the compound-science side of that line.

Why cognition endpoints punish inconsistent material

This is the part of the topic most suppliers skip, and it is the part that actually affects your customers' work.

Behavioral and cognitive assays produce small effect sizes with wide variance. When the signal you are looking for is subtle, anything that introduces systematic noise can swamp it — or worse, create the appearance of a result that is really a contaminant artifact.

Endotoxin is the clearest example. Bacterial endotoxin at levels that would be invisible in a tissue-repair assay can provoke sickness behavior in animal models, which degrades performance on exactly the tasks used to measure learning and memory. A lab running a cognition endpoint with an unscreened peptide may be measuring an inflammatory response and calling it a cognitive one. Truncated and deletion sequences from incomplete synthesis behave similarly: they are peptide, they show up in crude weight, and they may bind their target partially or not at all — producing a diluted, unpredictable dose of the actual compound.

Then there is the gap between purity and net peptide content. A vial can be 99% pure by HPLC and still contain considerably less active peptide by mass than the label suggests, because counterion salt (commonly TFA from purification) and residual water occupy part of that weight. Purity describes what fraction of the peptide present is the right peptide. Net peptide content describes how much peptide is in the vial at all. A supplier who reports one and not the other has told you half the story.

Batch-to-batch variability is the last trap. Longitudinal designs and dose-response curves assume the material is the same across the study. If lot two differs meaningfully from lot one, the study is compromised and nobody finds out until the data refuses to make sense. Repeatability is a supply-chain property before it is a scientific one.

The verification checklist worth applying to any supplier

The questions below apply to every research peptide, but they carry extra weight when the end use involves subtle endpoints.

If a supplier resists any row in that table, the resistance is the answer. Third-party verification exists precisely so buyers do not have to trust a vendor's self-description.

Compliance questions that belong with your counsel

This section is informational and is not legal advice.

The regulatory position of research peptides is not a settled fact you can look up once and file away, and anyone who tells you otherwise is guessing. Treat it as a set of questions to resolve with your own attorney and your state licensing board before you stock anything: How does your jurisdiction characterize research-use-only materials for a business in your category? What labeling and recordkeeping obligations attach to holding and reselling them? Does your professional license, or your entity structure, change the answer? What does your liability carrier require? If you resell, what representations are you permitted to make in your own marketing, and which ones create exposure regardless of what a supplier's page says?

None of those questions have generic answers, and a peptide supplier is not the right party to answer them. Real Peptides supplies research-use-only material and documentation; your compliance posture is your counsel's domain.

If your work or your customers' work involves live animals, animal welfare, husbandry, and permissible use questions belong with your veterinarian and your institution's oversight process — talk to your veterinarian before any live-animal design is finalized. These compounds are not for human or veterinary administration.

What Real Peptides does differently

The Wholesale Partner Program is built around removing the verification friction described above rather than charging for it.

Every compound in the catalog is held to a 99%+ HPLC purity standard. Every batch runs through a seven-panel test protocol, and the results are published rather than summarized — the COAs are publicly verifiable, so a prospective partner can check the lab results before applying, without a sales conversation and without paying for the document. That is a deliberate contrast with the common industry pattern of hiding pricing behind an application, describing testing without documenting it, or treating a certificate of analysis as a paid add-on.

Fulfillment is US-based, with orders shipping in five to seven days. Wholesale pricing is tiered and disclosed, so a reseller or clinic operator can model a catalog before committing. The application itself is three steps: submit the business application, get approved, and place your first wholesale order against published tier pricing.

One more thing worth saying plainly, because the category is full of ambiguity: the catalog is what it is. Real Peptides does not supply semaglutide, tirzepatide, retatrutide, or Melanotan II, and no wholesale conversation will produce them.

If you are evaluating whether to add research peptides to your catalog and you want documentation you can verify before you commit, the Wholesale Partner Program application is the next step — the COAs are available to review first, which is the order most buyers prefer.

Researchers working adjacent to the GH axis often look at related signaling compounds, including Tesamorelin 10mg within the broader growth factor and tissue signaling research collection, while cognition-adjacent catalogs frequently include Selank Liquid Spray 45mg; the longevity research collection and the popular peptides collection cover the rest of the range most wholesale partners stock.